EAEinas Al-Kuwari

Einas Al-Kuwari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Einas Al-Kuwari has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Two Versus One COVID-19 Vaccine Dose After Prior SARS-CoV-2 Infection: A Nationwide Retrospective Cohort Study

    by Hiam Chemaitelly, Houssein H Ayoub, Peter Coyle, Patrick Tang, Mohammad R Hasan, Hadi M Yassine, Asmaa A Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Background: Immune protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varies by prior infection and vaccination history. This study evaluated whether 2 coronavirus disease (COVID-19) vaccine doses after prior infection provide additional protection compared with a single dose. Methods: A national matched retrospective cohort study was conducted in Qatar from December 1, 2020-March 3, 2025. Incidence of SARS-CoV-2 reinfection and severe COVID-19 at reinfection was compared between 61 854 previously infected individuals who completed primary-series vaccination (2-dose cohort) and 61 854 matched individuals who received a single dose (single-dose cohort). Results: After 360 days of follow-up, cumulative incidence of reinfection was 5.0% (95% CI, 3.8%–6.7%) in the 2-dose cohort and 7.7% (95% CI, 6.1%–9.6%) in the single-dose cohort. No reinfections progressed to severe, critical, or fatal COVID-19 in either cohort. Relative vaccine effectiveness (rVE) of 2 doses vs 1 dose was 38.9% (95% CI, 20.4%–53.2%). The rVE was 26.9% (95% CI, −12.7%–53.4%) within <24 days, 51.8% (95% CI, 19.2%–71.2%) during Days 24–179, and 36.8% (95% CI, 0.9%–59.7%) at ≥180 days of follow-up. Subgroup analyses by time between prior infection and vaccination, prior infection variant, and vaccine type yielded broadly similar rVE estimates, while analyses stratified by age and clinical vulnerability suggested higher point estimates among older and clinically vulnerable individuals. Conclusions: Among individuals with prior infection, completion of primary-series vaccination provided modest additional protection against reinfection compared with a single dose. These findings support risk-based dose-optimization strategies in settings with constrained vaccine supply.

  • Open Access

    Assessing the Impact of the Healthy Vaccinee Effect on COVID-19 Vaccine Effectiveness Estimates

    by Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Background: Health status influences uptake of COVID-19 vaccination, with vaccinated individuals generally being healthier than their unvaccinated counterparts. However, the extent to which this healthy vaccinee effect biases vaccine effectiveness estimates remains unclear. This study investigated how different levels of the healthy vaccinee effect may impact these estimates. Methods: Three national, matched, retrospective cohort studies were conducted on the population of Qatar from February 5, 2020-May 14, 2024, to estimate effectiveness of primary- series and booster vaccinations and of natural infection against infection and reinfection. The studies explored three different scenarios for matching by coexisting conditions, each reflecting a different level of health-status imbalance between vaccinated and unvaccinated individuals. Results: Estimated effectiveness of primary-series and booster vaccinations against infection and against severe, critical, or fatal COVID-19 showed consistent values across the different matching strategies, despite varying hazard ratios for non-COVID-19 deaths. For example, primary-series effectiveness against severe, critical, or fatal COVID-19 was 96.3% (95% CI: 94.5-97.5) when matching by exact coexisting condition types, 94.2% (95% CI: 92.5-95.6) when matching by number of coexisting conditions, and 94.0% (95% CI: 92.3-95.3) with no matching by coexisting conditions. Similar results were observed when the analysis was stratified by the duration of follow-up and for the subgroup of individuals clinically vulnerable to severe COVID-19. Analogous results were found for effectiveness of natural infection against reinfection and against severe, critical, or fatal COVID-19 upon reinfection. Conclusion: The imbalance in health status between vaccinated and unvaccinated individuals in real-world conditions did not introduce a healthy vaccinee bias into the estimated vaccine effectiveness.

  • Open Access

    Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar

    by Layan Sukik, Hiam Chemaitelly, Houssein H Ayoub, Peter Coyle, Patrick Tang, Mohammad R Hasan, Hadi M Yassine, Asmaa A Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, et al.

    Background: Accurately assessing SARS-CoV-2 infection severity is essential for understanding the health impact of the infection and evaluating the effectiveness of interventions. This study investigated whether SARS-CoV-2–associated hospitalizations can reliably measure true COVID-19 severity. Methods: The diagnostic accuracy of SARS-CoV-2–associated acute care and ICU hospitalizations as indicators of infection severity was assessed in Qatar from 6 September 2021 to 13 May 2024. WHO criteria for severe, critical, and fatal COVID-19 served as the reference standard. Two indicators were assessed: (1) any SARS-CoV-2–associated hospitalization in acute care or ICU beds and (2) ICU-only hospitalizations. Results: A total of 644 176 SARS-CoV-2 infections were analyzed. The percent agreement between any SARS-CoV-2–associated hospitalization (acute care or ICU) and WHO criteria was 98.7% (95% confidence interval (CI), 98.6–98.7); however, Cohen's kappa was only 0.17 (95% CI, 0.16–0.18), indicating poor agreement. Sensitivity, specificity, PPV, and negative predictive value were 100% (95% CI, 99.6–100), 98.7% (95% CI, 98.6–98.7), 9.7% (95% CI, 9.1–10.3), and 100% (95% CI, 100–100), respectively. For SARS-CoV-2–associated ICU-only hospitalizations, the percent agreement was 99.8% (95% CI, 99.8–99.9), with a kappa of 0.47 (95% CI, 0.44–0.50), indicating fair-to-good agreement. Sensitivity, specificity, PPV, and negative predictive value were 46.6% (95% CI, 43.4–49.9), 99.9% (95% CI, 99.9–99.9), 47.9% (95% CI, 44.6–51.2), and 99.9% (95% CI, 99.9–99.9), respectively. Conclusions: Generic hospital admissions are unreliable indicators of COVID-19 severity, whereas ICU admissions are somewhat more accurate. The findings demonstrate the importance of applying specific, robust criteria—such as WHO criteria—to reduce bias in epidemiological and vaccine effectiveness studies.


  • Open Access

    Assessing Healthy Vaccinee Effect in COVID-19 Vaccine Effectiveness Studies: A National Cohort Study in Qatar

    by Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Background: This study investigated the presence of the healthy vaccinee bias in two COVID-19 vaccine effectiveness studies, involving primary series and booster vaccinations, as well as its temporal patterns and variability across different subpopulations, by examining the association between COVID-19 vaccination and non-COVID-19 mortality in Qatar. Methods: Two matched, retrospective cohort studies assessed the incidence of non-COVID-19 death in national cohorts of individuals with a primary series vaccination versus no vaccination (two-dose analysis), and individuals with three-dose (booster) vaccination versus primary series vaccination (three-dose analysis), from January 5, 2021, to April 9, 2024. Results: The adjusted hazard ratio (aHR) for non-COVID-19 death was 0.76 (95% CI: 0.64-0.90) in the two-dose analysis and 0.85 (95% CI: 0.67-1.07) in the three-dose analysis. In the first six months of follow-up in the two-dose analysis, the aHR was 0.35 (95% CI: 0.27-0.46); however, the combined analysis of all subsequent periods showed an aHR of 1.52 (95% CI: 1.19- 1.94). In the first six months of follow-up in the three-dose analysis, the aHR was 0.31 (95% CI: 0.20-0.50); however, the combined analysis of all subsequent periods showed an aHR of 1.37 (95% CI: 1.02-1.85). The overall effectiveness of the primary series and third-dose vaccinations against severe, critical, or fatal COVID-19 was 95.9% (95% CI: 94.0-97.1) and 34.1% (95% CI:-46.4-76.7), respectively. Subgroup analyses showed that the healthy vaccinee bias is pronounced among those aged 50 years and older and among those more clinically vulnerable to severe COVID-19. Conclusion: A strong healthy vaccinee bias was observed in the first six months following vaccination. This bias may have stemmed from a lower likelihood of vaccination among seriously ill, end-of-life individuals, and less mobile elderly populations. Despite this bias, vaccination provided strong protection against severe COVID-19.

  • Open Access

    SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study

    by Mai A. Mahmoud, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Asmaa A. Al Thani, Zaina Al‐Kanaani, Einas Al‐Kuwari, Andrew Jeremijenko, et al.

    Background: We investigated the contribution of age, coexisting medical conditions, sex, and vaccination to incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and of severe, critical, or fatal COVID‐19 in older adults since pandemic onset.Methods: A national retrospective cohort study was conducted in the population of Qatar aged ≥50 years between February 5, 2020 and June 15, 2023. Adjusted hazard ratios (AHRs) for infection and for severe coronavirus disease 2019 (COVID‐19) outcomes were estimated through Cox regression models.Results: Cumulative incidence was 25.01% (95% confidence interval [CI]: 24.86–25.15%) for infection and 1.59% (95% CI: 1.55–1.64%) for severe, critical, or fatal COVID‐19 after a follow‐up duration of 40.9 months. Risk of infection varied minimally by age and sex but increased significantly with coexisting conditions. Risk of infection was reduced with primary‐series vaccination (AHR: 0.91, 95% CI: 0.90–0.93) and further with first booster vaccination (AHR: 0.75, 95% CI: 0.74–0.77). Risk of severe, critical, or fatal COVID‐19 increased exponentially with age and linearly with coexisting conditions. AHRs for severe, critical, or fatal COVID‐19 were 0.86 (95% CI: 0.7–0.97) for one dose, 0.15 (95% CI: 0.13–0.17) for primary‐series vaccination, and 0.11 (95% CI: 0.08–0.14) for first booster vaccination. Sensitivity analysis restricted to only Qataris yielded similar results.Conclusion: Incidence of severe COVID‐19 in older adults followed a dynamic pattern shaped by infection incidence, variant severity, and population immunity. Age, sex, and coexisting conditions were strong determinants of infection severity. Vaccine protection against severe outcomes showed a dose–response relationship, highlighting the importance of booster vaccination for older adults.


  • Open Access

    Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study

    by Suelen H. Qassim, Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Hadi M. Yassine, Asmaa A. Al Thani, Hebah A. Al-Khatib, Mohammad R. Hasan, Zaina Al-Kanaani, et al.


  • Open Access

    Patterns in Repeat Reinfections: Pre and Post Omicron Emergence

    by Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Peter Coyle, Hadi M. Yassine, Asmaa A. Al Thani, Mohammad R. Hasan, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, et al.

    Our understanding of SARS-CoV-2 reinfection patterns remains limited. We conducted a longitudinal study using Qatar’s national SARS-CoV-2 data from February 28, 2020 to June 11, 2023 to investigate incidence of reinfections both prior to and after omicron emergence. The latter analysis excluded individuals with pre-omicron infections. Before omicron introduction, the proportion of incident infections classified as reinfections gradually increased but remained minimal, reaching 1.8% just before omicron emerged. During the first omicron wave, this proportion reached 9.0%, a 5-fold increase. After the conclusion of the first omicron wave, the proportion of incident infections identified as reinfections rapidly increased, reaching 43.3% towards the end of the study. In the pre-omicron era, a total of 3,131 reinfections were documented, of which 99.6% were first reinfections and 0.4% were second reinfections. Meanwhile, a total of 20,962 reinfections were documented after an omicron primary infection of which 99.0% were first reinfections, 1.0% were second reinfections, and 0.01% were third reinfections. Reinfections were rare before omicron’s emergence but became widespread during the omicron era, including among individuals previously infected with omicron. Our findings may indicate accelerated viral evolution in the omicron era aimed at evading population immunity, but with minimal impact on COVID-19 severity, or potentially suggest immune imprinting effects that require further investigation.


  • Open Access

    Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: An observational study

    by Suelen H. Qassim, Hiam Chemaitelly, Houssein H. Ayoub, Peter Coyle, Patrick Tang, Hadi M. Yassine, Asmaa A. Al Thani, Hebah A. Al-Khatib, Mohammad R. Hasan, Zaina Al-Kanaani, et al.

    Summary: Background: Waning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination are defined, respectively, as the overall protection against reinfection or against breakthrough infection at a given point in time in a given population. Methods: We estimated these population immunities in Qatar’s population between July 1, 2020 and November 30, 2022, to discern generic features of the epidemiology of SARS-CoV-2. Effectiveness of previous infection, mRNA primary-series vaccination, and mRNA booster (third-dose) vaccination in preventing infection were estimated, month by month, using matched, test-negative, case-control studies. Findings: Previous-infection effectiveness against reinfection was strong before emergence of Omicron, but declined with time after a wave and rebounded after a new wave. Effectiveness dropped immediately after Omicron emergence from 88.3% (95% CI: 84.8-91.0%) in November 2021 to 51.0% (95% CI: 48.3-53.6%) in December 2021. Primary-series effectiveness against infection was 84.0% (95% CI: 83.0-85.0%) in April 2021, soon after introduction of vaccination, before waning gradually to 52.7% (95% CI: 46.5-58.2%) by November of 2021. Effectiveness declined linearly by ∼1 percentage point every 5 days. After Omicron emergence, effectiveness dropped suddenly from 52.7% (95% CI: 46.5-58.2%) in November 2021 to negligible levels in December 2021. Booster effectiveness dropped immediately after Omicron emergence from 83.0% (95% CI: 65.6 -91.6%) in November 2021 to 32.9% (95% CI: 26.7-38.5%) in December 2021, and continued to decline thereafter. Effectiveness of previous infection and vaccination against severe, critical, or fatal COVID-19 were generally >80% throughout the study duration. Interpretation: High population immunity may not be sustained beyond a year. This creates fertile grounds for repeated waves of infection to occur, but these waves may increasingly exhibit a benign pattern of infection. Funding: The Biomedical Research Program and the Biostatistics, Epidemiology, and the Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, Qatar University Biomedical Research Center, and Qatar University Internal Grant ID QUCG-CAS-23/24-114. Research in context: Evidence before this study: SARS-CoV-2 infection induces protection against reinfection, but this protection wanes with time since last infection. Similarly, COVID-19 primary-series and booster vaccination induce protection against SARS-CoV-2 infection, but this protection also wanes with time since last dose. These immunity patterns demonstrate the need for the concept of population immunity to track evolution of overall immune protection over time in a given population. Previous-infection and vaccine population immunities in a specific country can be defined as the overall protection against infection at a given point in time in the full national population. A search of PubMed, Google Scholar, and the International Vaccine Access Center’s VIEW-hub databases up to April 21, 2023 using the keywords “vaccination”, “infection”, “immunity”, “protection”, “SARS-CoV-2”, and “COVID-19” did not identify studies that investigated this epidemiological concept for a national population throughout the COVID-19 pandemic. Added value of this study: This study analyzed the national federated databases for SARS-CoV-2 infection and COVID-19 vaccination in Qatar, a country that experienced SARS-CoV-2 waves dominated by different pre-Omicron variants and Omicron subvariants. Using a matched, test-negative study design, population immunity against infection of each of previous infection, primary-series vaccination, and booster vaccination were characterized at the national level month by month for two calendar years to discern generic features of the epidemiology of SARS-CoV-2. The three forms of population immunity showed rapid variation over time driven by waning of protection. Vaccine-derived population immunity declined by 1 absolute percentage point every 5 days. Omicron introduction immensely reduced the three forms of population immunity within one month by about 50 absolute percentage points. Meanwhile, previous-infection and vaccine population immunities against severe COVID-19 were durable with slow waning even after Omicron emergence. Implications of all available evidence: Both previous-infection and vaccine population immunities vary rapidly at a national level creating fertile grounds for repeated waves of infection to occur even within months of each other. High levels of population immunity may not be sustained for more than a year or so. Preventing infection/reinfection, transmission, or future waves of infection cannot sustainably be done with current vaccines nor by the entire population being infected. Timely administration of boosters for those vulnerable to severe COVID-19 may remain essential for years to come. Repeated waves of infection may also facilitate further evolution of the virus and continual immune evasion. Emergence of a new variant that is substantially different from circulating variants can suddenly and immensely reduce population immunity leading to large epidemic waves. However, the durability of population immunity against severe COVID-19 will likely curtail the severity of future waves.


  • Open Access

    Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta infections

    by Heba N. N. Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Hebah A. Al-Khatib, Asmaa A. Al Thani, Peter Coyle, Zaina Al-Kanaani, et al.

    Background: Protection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination were investigated in Qatar for the Alpha, Beta, and Delta variants. Methods: Six national, matched, test-negative, case-control studies were conducted between January 18-December 18, 2021 on a sample of 239,120 PCR-positive tests and 6,103,365 PCR-negative tests. Results: Effectiveness of previous infection against Alpha, Beta, and Delta reinfection was 89.5% (95% CI: 85.5-92.3%), 87.9% (95% CI: 85.4-89.9%), and 90.0% (95% CI: 86.7-92.5%), respectively. Effectiveness of two-dose BNT162b2 vaccination against Alpha, Beta, and Delta infection was 90.5% (95% CI, 83.9-94.4%), 80.5% (95% CI: 79.0-82.0%), and 58.1% (95% CI: 54.6-61.3%), respectively. Effectiveness of three-dose BNT162b2 vaccination against Delta infection was 91.7% (95% CI: 87.1-94.7%). Effectiveness of hybrid immunity of previous infection and two-dose BNT162b2 vaccination was 97.4% (95% CI: 95.4-98.5%) against Beta infection and 94.5% (95% CI: 92.8-95.8%) against Delta infection. Effectiveness of previous infection and three-dose BNT162b2 vaccination was 98.1% (95% CI: 85.7-99.7%) against Delta infection. All five forms of immunity had >90% protection against severe, critical, or fatal COVID-19 regardless of variant. Similar effectiveness estimates were observed for mRNA-1273. Conclusions: All forms of natural and vaccine immunity prior to Omicron introduction provided strong protection against infection and severe COVID-19. Hybrid immunity conferred the strongest protection and its level was consistent with previous-infection immunity and vaccine immunity acting independently of each other.


  • Open Access

    Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections

    by Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, Jeremy Samuel Faust, Patrick Tang, Peter Coyle, Hadi M. Yassine, Asmaa A. Al Thani, Hebah A. Al-Khatib, Mohammad R. Hasan, et al.

    Qatar introduced COVID-19 bivalent vaccination for persons ≥12 years old using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains. We estimated effectiveness of this bivalent vaccine against SARS-CoV-2 infection using a matched, retrospective, cohort study. Matched cohorts included 11,482 persons in the bivalent cohort and 56,806 persons in the no-recent-vaccination cohort. During follow-up, 65 infections were recorded in the bivalent cohort and 406 were recorded in the no-recent-vaccination cohort. None progressed to severe, critical, or fatal COVID-19. Cumulative incidence of infection was 0.80% (95% CI: 0.61-1.07%) in the bivalent cohort and 1.00% (95% CI: 0.89-1.11%) in the no-recent- vaccination cohort, 150 days after the start of follow-up. Incidence during follow-up was dominated by omicron XBB* subvariants including XBB, XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.9.2, XBB.1.16, and XBB.2.3. The adjusted hazard ratio comparing incidence of infection in the bivalent cohort to that in the no-recent-vaccination cohort was 0.75 (95% CI: 0.57-0.97). Bivalent vaccine effectiveness against infection was 25.2% (95% CI: 2.6-42.6%). Effectiveness was 21.5% (95% CI: -8.2-43.5%) among persons with no prior infection and 33.3% (95% CI: - 4.6-57.6%) among persons with prior infection. mRNA-1273.214 reduced incidence of SARS- CoV-2 infection, but the protection was modest at only 25%. The modest protection may have risen because of XBB* immune evasion or immune imprinting effects, or combination of both.